Artificially modified peptide derived from tilapia antibacterial peptide piscidin 4 and application thereof

By designing and synthesizing artificially modified peptide TP16G4C, the cytotoxicity and stability problems of the natural antimicrobial peptide piscidin 4 of tilapia were solved, low hemolysis and high stability were achieved, good antimicrobial activity was maintained, and suitable for a variety of applications.

CN119019524APending Publication Date: 2024-11-26GERMPLASM INNOVATION GRAND SCIENCE CENTER OF WESTERN CHINA (CHONGQING) SCIENCE CITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411444404.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The natural antimicrobial peptide of tilapia piscidin 4 has problems with high cytotoxicity and poor stability, which limits its application.

Method used

Design and artificially synthesize a artificially modified peptide TP16G4C with low hemolysis rate, high stability and good antibacterial activity. By cutting off the first 9 amino acids of the N-terminal and replacing the fourth amino acid Gly as Cys, and performing C-terminal amidation. Purification was improved by solid-phase chemical synthesis and reverse-phase high-performance liquid chromatography.

Benefits of technology

The low hemolysis and high stability of TP16G4C were achieved, which significantly reduced the cytotoxicity, maintained good antibacterial activity, and had obvious inhibitory effects on a variety of pathogens. It is suitable for the preparation of antibacterial agents and other products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019524A_ABST
    Figure CN119019524A_ABST
Patent Text Reader

Abstract

The invention discloses an artificially modified antibacterial peptide TP16G4C as well as a preparation method and application thereof, and relates to the technical field of biology. On the basis of the amino acid sequence of the tilapia antibacterial peptide piscidin 4, through prediction and sequence analysis, the first 9 amino acids at the N end of the tilapia antibacterial peptide piscidin 4 are cut off, the fourth amino acid glycine of the truncated 16 peptide is replaced with cysteine, and the C end is amidated. Compared with tilapia mossambica antibacterial peptide piscidin 4, the hemolytic activity of the artificially modified antibacterial peptide TP16G4C is reduced, and the protease stability is improved. Meanwhile, good antibacterial activity is still kept. The artificially modified antibacterial peptide TP16G4C is convenient to synthesize, low in cost, small in side effect and good in stability, and wide prospects are provided for application of the antibacterial peptide in food, medicine, agriculture and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to an artificially modified peptide derived from tilapia antibacterial peptide piscidin 4 and application thereof. Background Art

[0002] Antimicrobial peptides are naturally present in a variety of organisms with antibacterial activity. Compared with antibiotics, antimicrobial peptides have the characteristics of a broad antimicrobial spectrum and are not easy to induce drug resistance. They are widely used in medicine, animal husbandry and food industries. Tilapia antimicrobial peptide piscidin4 (TP4) has good antibacterial effect and has antibacterial effects on a variety of aquatic pathogens including Streptococcus agalactiae, Aeromonas hydrophila, Vibrio vulnificus, Streptococcus dolphinus, Vibrio anguillarum, etc. At the same time, TP4 has also been shown to have the effects of promoting wound healing and inhibiting cancer. However, like many other natural antimicrobial peptides, TP4 has problems such as poor stability and high cytotoxicity, which limits its application. Therefore, how to reduce cytotoxicity and improve its stability is an urgent problem to be solved in the current research and development of TP4. Summary of the invention

[0003] In order to solve the problems of high cytotoxicity and poor stability of tilapia natural antimicrobial peptide piscidin 4 (TP4), the present invention provides an artificially modified peptide TP16G4C with low hemolysis rate, high stability and good antimicrobial activity, and also provides methods for its sequence optimization design, artificial synthesis and purification, and its application in the preparation of antimicrobial products.

[0004] To achieve the above object, the present invention adopts the following technical solutions:

[0005] In a first aspect, the present invention provides an artificially modified peptide TP16G4C derived from tilapia antimicrobial peptide piscidin 4, wherein the amino acid sequence of the artificially modified peptide is FSACKAIHRLIRRRRR, as shown in SEQ ID NO. 1. The sequence of tilapia antimicrobial peptide piscidin 4 is FIHHIIGGLFSAGKAIHRLIRRRRR (GenBank: QCX36736.1). In addition, the present invention also provides a DNA encoding the artificially modified peptide TP16G4C.

[0006] In a second aspect, the present invention provides a method for preparing the artificially modified peptide TP16G4C as described in the first aspect, the method comprising the following steps:

[0007] (1) Design of artificial modified peptide TP16G4C: the first 9 amino acids of the N-terminus of tilapia antimicrobial peptide piscidin 4 were truncated, the 4th amino acid Gly of the truncated 16-peptide was replaced by Cys, and the C-terminus was amidated to generate artificial modified peptide TP16G4C;

[0008] (2) The entire sequence of the artificially engineered peptide TP16G4C was synthesized using solid-phase chemical synthesis;

[0009] (3) purification by reverse phase high performance liquid chromatography;

[0010] 4) The purified peptide solution is reacted under air oxygen and alkaline conditions at room temperature to complete the preparation of the artificially modified peptide TP16G4C.

[0011] Furthermore, the artificially modified peptide TP16G4C can also be prepared by in vitro expression, such as by in vitro expression of an expression vector containing the DNA encoding the artificially modified peptide TP16G4C, and amidation of the C-terminus of the expressed artificially modified peptide TP16G4C to improve its storage stability.

[0012] In a third aspect, the present invention provides an antibacterial application of the artificially modified peptide TP16G4C as described in the first aspect. Since the artificially modified peptide TP16G4C has excellent antibacterial ability, low hemolysis and high stability, it can be used to prepare an antibacterial agent.

[0013] In a fourth aspect, the present invention provides the use of the artificially modified peptide TP16G4C as described in the first aspect in the preparation of food, medicine, cosmetics, sanitary products, and agricultural products. Since the artificially modified peptide TP16G4C has excellent antibacterial ability, low hemolysis and high stability, it can be used in the preparation of food, medicine, cosmetics, sanitary products, and agricultural products.

[0014] The beneficial effects of the present invention are:

[0015] The technology for preparing the artificial modified peptide TP16G4C by the method of the present invention is simple, and the obtained artificial modified peptide TP16G4C has good antibacterial activity, low hemolysis and high stability, and has obvious inhibitory effects on tilapia agalactiae Streptococcus, Pitt's Acinetobacter, etc. In summary, the artificial modified peptide TP16G4C is an antibacterial peptide with great application value.

[0016] Other advantages, objectives and features of the present invention will be described in the following description to some extent, and to some extent, will be obvious to those skilled in the art based on the following examination and study, or can be taught from the practice of the present invention. The objectives and other advantages of the present invention can be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:

[0018] Figure 1To artificially modify the physicochemical properties of the peptide TP16G4C.

[0019] Figure 2 This is the reverse liquid chromatography of the artificially modified peptide TP16G4C.

[0020] Figure 3 This is the mass spectrum of the artificially modified peptide TP16G4C.

[0021] Figure 4 The minimum inhibitory concentration of the artificially modified peptide TP16G4C against different bacteria.

[0022] Figure 5 is the hemolysis rate of the artificially modified peptide TP16G4C.

[0023] Figure 6 To investigate the stability of the artificially modified peptide TP16G4C under treatment with different proteases, serum, temperature, pH and salt. DETAILED DESCRIPTION

[0024] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0025] The present invention is further described in detail below in conjunction with embodiments:

[0026] Example 1

[0027] Design of artificially modified peptide TP16G4C:

[0028] The sequence of tilapia antimicrobial peptide piscidin 4 is FIHHIIGGLFSAGKAIHRLIRRRRR (GenBank: QCX36736.1).

[0029] Through prediction and sequence analysis, the first 9 amino acids at the N-terminus of the tilapia antimicrobial peptide piscidin 4 were truncated, the 4th amino acid Gly of the truncated 16-peptide was replaced by Cys, and the C-terminus was amidated to generate an artificially modified peptide TP16G4C. The sequence of the artificially modified peptide TP16G4C is FSACKAIHRLIRRRRR, as shown in SEQ ID NO.1.

[0030] Example 2 Preparation of artificially modified peptide TP16G4C by solid phase chemical synthesis

[0031] 1. The synthetic sequence of the artificially modified peptide TP16G4C was from C-terminus to N-terminus;

[0032] 2. Weigh X mmol (X is an arbitrary value, depending on the target yield) equivalent of resin into the reactor, add the reaction solvent dichloromethane to swell for half an hour and then remove it, add the first amino acid in the sequence (X mmol), diisopropylethylamine, dimethylformamide, dichloromethane, and react with nitrogen bubbling for 1 hour. Add 5X mmol equivalent of methanol to react for half an hour, remove the reaction solution, and wash with dimethylformamide and dichloromethane;

[0033] 3. Add an appropriate amount of 20% piperidine to remove the 9-fluorenylmethoxycarbonyl (Fmoc) protecting group, wash and detect;

[0034] 4. Add the second amino acid in the sequence (3X mmol), 3X mmol benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) and 3X mmol diisopropylethylamine into the reactor. After nitrogen bubbling for half an hour, remove the liquid, wash with dimethylformamide and dichloromethane, and detect with ninhydrin;

[0035] 5. Add other amino acids in the sequence in sequence according to steps 3 and 4, remove the liquid, wash and test;

[0036] 6. Dry the resin with nitrogen, remove the resin from the reaction column and weigh it. Pour the resin into a flask and add a certain amount of 95% trifluoroacetic acid (TFA) to it, and shake it for 2 hours;

[0037] 7. Filter off the resin and take the filtrate. Add a large amount of ether to the filtrate to precipitate the crude product. Then centrifuge and wash;

[0038] 8. Use electrospray ionization source mass spectrometer to detect the correctness of the molecular weight of the sequence, and use high performance liquid chromatography to purify the crude product to the required purity;

[0039] 9. The purified peptide solution is placed in a freeze dryer for concentration and freeze drying;

[0040] 10. Dissolve the peptide in water (1 mg / mL) and place the peptide solution in the presence of air oxygen and alkaline conditions (0.1 M NH4HCO3) at room temperature for 18-24 hours.

[0041] TP16G4C theoretical parameters are as follows Figure 1 As shown, its theoretical molecular weight is 2038.5 g / mol. Figure 2 The reverse liquid chromatography of the synthetic peptide TP16G4C shows that its purity is greater than 95%. Figure 3 As shown in the mass spectrum, the molecular weight of the artificially modified peptide TP16G4C is 2038.5 g / mol, and the theoretical molecular weight is consistent with the measured molecular weight.

[0042] Example 3 Determination of the biological activity of the artificially modified peptide TP16G4C

[0043] The minimum inhibitory concentration of the artificially modified peptide TP16G4C against common pathogens was determined by the microbroth dilution method. The pathogens were cultured to the exponential growth phase and the cell density was 1.5×10 6 CFU / mL of bacterial suspension. Mueller-Hinton (MH) medium and artificially modified peptide were added to the wells of a 96-well plate with a total volume of 100 μL. The final concentrations of TP16G4C were 32, 16, 8, 4, 2, 1, 0.5, 0.25, and 0.125 μg / mL by serial dilution. 100 μL of bacterial suspension was added to each well. 200 μL of MH medium and 200 μL of bacterial suspension were added as negative and positive controls, respectively. The 96-well plate was cultured at 37°C for 18-24 hours. The lowest concentration of the transparent culture medium without turbidity is the minimum inhibitory concentration (MIC).

[0044] The results are as follows Figure 4 As shown, TP16G4C has an antibacterial effect on Gram-negative bacteria including Escherichia coli, Aeromonas hydrophila, Acinetobacter pituitii, and Acinetobacter baumannii, as well as Gram-positive bacteria including Staphylococcus aureus, Streptococcus agalactiae, and methicillin-resistant Staphylococcus aureus.

[0045] Example 4 Hemolytic effect of artificially modified peptide TP16G4C

[0046] The cytotoxicity of the artificially modified peptide TP16G4C was evaluated by the release of hemoglobin in fish erythrocytes. Venous blood was drawn from tilapia, centrifuged at 4000r / min for 10 minutes to separate the erythrocytes, and washed with PBS. After discarding the PBS, the erythrocytes were resuspended in PBS to a volume fraction of 10%. Subsequently, the erythrocytes were incubated with different concentrations (0, 1.95, 3.91, 7.81, 15.63, 31.25, 62.5, 125, 250 μg / mL) of TP16G4C and TP4 at 22°C for 1 hour. Erythrocytes without the addition of antimicrobial peptides were used as negative controls, and erythrocytes containing 0.2% Triton-X were used as positive controls. The incubated mixture was centrifuged at 4000r / min for 5 minutes, and the supernatant was collected to measure the OD 540 .

[0047] The formula for calculating the hemolysis rate is: Hemolysis rate = (OD 处理 -OD 阴性 ) / (OD 阳性 -OD 阴性 )×100%.

[0048] Test results such as Figure 5As shown, the hemolytic rate of the artificially modified peptide TP16G4C was significantly lower than that of the natural peptide TP4, and its toxicity to red blood cells was weakened.

[0049] Example 5 Stability determination of artificially modified peptide TP16G4C

[0050] The antibacterial activity of the artificially modified peptide TP16G4C against Streptococcus agalactiae was determined under different conditions of temperature, pH, salt, protease and serum treatment.

[0051] To evaluate thermal stability, TP16G4C adjusted to 32 μg / mL with brain heart infusion broth (BHI) was treated at 60°C and 100°C for 0.5, 1, and 2 hours, respectively, and then cooled to room temperature.

[0052] For pH stability testing, TP16G4C adjusted to 32 μg / mL with BHI was adjusted to pH 3, 4, 5, 6, 7, 8, 9 and treated for 1 hour before being adjusted to pH 7.

[0053] In the salt stability experiment, TP16G4C was treated with 150 mM NaCl and 4.5 mM KCl for 1 h, respectively, and then the peptide concentration was adjusted to 32 μg / mL with BHI medium.

[0054] The stability of the protease was evaluated by trypsin (trypsin), proteinase K or collagenase. The protease (1 mg / mL) was incubated with TP16G4C at a volume of 1:1 at 37°C for 1 hour, and then the peptide concentration was adjusted to 32 μg / mL with BHI medium.

[0055] To determine the stability of the peptide in serum, TP16G4C was treated with 25% and 75% fish serum for 1 h, and then the peptide concentration was adjusted to 32 μg / mL with BHI medium.

[0056] 100 μL of the treated peptide solution and 100 μL of Streptococcus agalactiae suspension (1.5×10 6 CFU / mL) for antibacterial experiments. The positive and negative controls were 200 μL of bacterial solution and 200 μL of BHI, respectively. Incubate at 37°C for 12 hours and measure OD 600 , and calculated the inhibition rate of antimicrobial peptides under different treatments.

[0057] The formula for calculating the antibacterial rate is: Antibacterial rate = (OD 处理 -OD 阴性 ) / (OD 阳性 -OD 阴性 )×100%.

[0058] The results are as follows Figure 6As shown, the protease stability and serum stability of the artificially modified peptide TP16G4C are improved compared with the natural peptide TP4 ( Figure 6 A), while its thermal stability, pH stability and salt stability remain good ( Figure 6 B, C, D).

[0059] The above results show that the length of the artificially modified peptide TP16G4C is shortened and the production cost is reduced. The artificially modified peptide TP16G4C still maintains good antibacterial activity. At the same time, compared with the natural peptide TP4, the cytotoxicity of TP16G4C is reduced and the protease stability is improved. In summary, it shows that the artificially modified peptide TP16G4C has great application value.

[0060] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.

Claims

1. An artificially modified peptide TP16G4C, characterized in that: The sequence of the artificially modified peptide TP16G4C is shown in SEQ ID NO. 1, and the C-terminus of the artificially modified peptide TP16G4C is amidated.

2. A DNA encoding the artificially modified peptide TP16G4C according to claim 1.

3. An expression vector containing the DNA of claim 2.

4. A method for preparing the artificially modified peptide TP16G4C according to claim 1, characterized in that: Includes the following: (1) Design of the artificially modified peptide TP16G4C: the N-terminal amino acid sequence of the antibacterial piscidin 4 of tilapia was truncated to 16 amino acids, the fourth amino acid Gly was replaced by Cys, and the C-terminus was amidated; (2) artificially synthesizing its entire sequence using solid-phase chemical synthesis; (3) purification by reverse phase high performance liquid chromatography; (4) The purified peptide solution was reacted under air oxygen and alkaline conditions at room temperature to complete the preparation of the artificially modified peptide TP16G4C.

5. Use of the artificially modified peptide TP16G4C according to claim 1 in antibacterial aspects.

6. Use of the artificially modified peptide TP16G4C according to claim 1 in the preparation of food, medicine, cosmetics, sanitary products and agricultural products.